GGP rejects $14.8bn buyout bid from Brookfield Property

By Pouyan Broukhim
Share

With mall owner GGP having confirmed a $14.8bn buyout proposal from shareholder Brookfield Property in mid-November, the company has now reportedly rejected the offer according to a number of sources.

Both Reuters and Bloomberg have cited “people familiar to the matter” in breaking the news, announced Sunday.

See also:

Brookfield made an offer of $23 per share for the remaining 66% interest the company, already acting as the largest shareholder in GGP with a 34% stake.

“The Board has formed a special committee of its non-executive, independent directors which, in consultation with its financial and legal advisors, will carefully review and consider the Proposal and pursue the course of action that it believes is in the best interests of the company’s stockholders,” GGP said in a statement at the time of the offer.

Brookfield, the landholdings arm of Toronto’s Brookfield asset management, is seeking full ownership of the US-based mall owner that currently owns approximately 127 properties.

The offer that was reportedly rejected was a part-cash, part-stock offer.

It remains it be seen whether Brookfield will continue to pursue a complete acquisition of GGP, with no official announcement having been made as of yet.

Share

Featured Articles

What is Nestlé CEO Laurent Freixe’s Action Plan?

Newly appointed CEO sets out action plan involving separating water brands into standalone business and boosting advertising and marketing spend

Will Mulberry Turn a New Leaf Under CEO Andrea Baldo?

International British luxury brand cuts quarter of head office staff as newly appointed CEO conducts strategic review

Female Board Members of Biggest UK Companies Paid 69% Less

Female board members of FTSE 100 companies are paid 69% less than male counterparts, as they find themselves frozen out of the biggest roles

Is This the Next CEO of LVMH?

Leadership & Strategy

How Burberry’s New CEO Is Going Back to Basics

Leadership & Strategy

Is Bayer CEO Bill Anderson Running Out of Time?

Leadership & Strategy